Movatterモバイル変換

[0]ホーム
URL:

UY31290A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-O-GLUCOSIDO - Google Patents

PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-O-GLUCOSIDO

Info

Publication number
UY31290A1
UY31290A1UY31290AUY31290AUY31290A1UY 31290 A1UY31290 A1UY 31290A1UY 31290 AUY31290 AUY 31290AUY 31290 AUY31290 AUY 31290AUY 31290 A1UY31290 A1UY 31290A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
derivative
glucosido
pirazol
diabetes mellitus
Prior art date
Application number
UY31290A
Other languages
Spanish (es)
Inventor
Klaus Dugi
Michael Mark
Frank Himmelsbach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Publication of UY31290A1publicationCriticalpatent/UY31290A1/en

Links

Classifications

Landscapes

Abstract

Translated fromSpanish

La invencion se refiere a una composicion faramcéutica segun la reivindicacion 1, que comprende un derivado de pirazol-O-glucosido en combinacion con un inhibidor de DPP IV que resulta adecuado en el tratamiento o prevencion de una o más afecciones seleccionadas de diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, tolerancia anormal a la glucosa e hiperglucemia. Además, la presente invencion se refiere a métodos para prevenir o tratar trastornos metabolicos y afecciones relacionadas.The invention relates to a pharmaceutical composition according to claim 1, which comprises a pyrazole-O-glucoside derivative in combination with a DPP IV inhibitor that is suitable in the treatment or prevention of one or more selected conditions of diabetes mellitus type 1, type 2 diabetes mellitus, abnormal glucose tolerance and hyperglycemia. In addition, the present invention relates to methods for preventing or treating metabolic disorders and related conditions.

UY31290A2007-08-162008-08-14 PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-O-GLUCOSIDOUY31290A1 (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
EP071144612007-08-16

Publications (1)

Publication NumberPublication Date
UY31290A1true UY31290A1 (en)2009-03-31

Family

ID=39870441

Family Applications (1)

Application NumberTitlePriority DateFiling Date
UY31290AUY31290A1 (en)2007-08-162008-08-14 PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-O-GLUCOSIDO

Country Status (6)

CountryLink
AR (1)AR068102A1 (en)
CL (1)CL2008002424A1 (en)
PE (1)PE20090987A1 (en)
TW (1)TW200918078A (en)
UY (1)UY31290A1 (en)
WO (1)WO2009022009A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7407955B2 (en)2002-08-212008-08-05Boehringer Ingelheim Pharma Gmbh & Co., Kg8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (en)2004-11-052006-05-11Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
PE20110235A1 (en)2006-05-042011-04-14Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
EP1852108A1 (en)2006-05-042007-11-07Boehringer Ingelheim Pharma GmbH & Co.KGDPP IV inhibitor formulations
EP2016079A1 (en)2006-05-042009-01-21Boehringer Ingelheim International GmbHPolymorphs
EP2120885A2 (en)*2007-03-132009-11-25Takeda Pharmaceutical Company LimitedSolid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile
CL2008002427A1 (en)2007-08-162009-09-11Boehringer Ingelheim Int Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
CL2008003653A1 (en)*2008-01-172010-03-05Mitsubishi Tanabe Pharma Corp Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
PE20140960A1 (en)2008-04-032014-08-15Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
PE20100156A1 (en)*2008-06-032010-02-23Boehringer Ingelheim Int NAFLD TREATMENT
KR20200118243A (en)2008-08-062020-10-14베링거 인겔하임 인터내셔날 게엠베하Treatment for diabetes in patients inappropriate for metformin therapy
US20200155558A1 (en)2018-11-202020-05-21Boehringer Ingelheim International GmbhTreatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010072776A1 (en)2008-12-232010-07-01Boehringer Ingelheim International GmbhSalt forms of organic compound
PL2395983T3 (en)2009-02-132020-09-07Boehringer Ingelheim International GmbhPharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
ES2760917T3 (en)2009-11-272020-05-18Boehringer Ingelheim Int Treatment of diabetic patients genotyped with DPP-IV inhibitors such as linagliptin
JP6034781B2 (en)2010-05-052016-11-30ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy
PH12012502524A1 (en)2010-06-242014-02-10Boehringer Ingelheim IntDiabetes therapy
AR083878A1 (en)2010-11-152013-03-27Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
AR085689A1 (en)2011-03-072013-10-23Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
HUE043540T2 (en)2011-07-152019-08-28Boehringer Ingelheim Int Preparation and Use of Substituted Dimer Quinazoline Derivatives in Medicinal Products for the Treatment of Type 1 and Type 2 Diabetes
US9555001B2 (en)2012-03-072017-01-31Boehringer Ingelheim International GmbhPharmaceutical composition and uses thereof
EP2849755A1 (en)2012-05-142015-03-25Boehringer Ingelheim International GmbHA xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
US20130303554A1 (en)2012-05-142013-11-14Boehringer Ingelheim International GmbhUse of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en)2012-05-242013-11-28Boehringer Ingelheim International GmbhA xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en)2014-02-282023-06-28Boehringer Ingelheim International GmbHMedical use of a dpp-4 inhibitor
JP2019517542A (en)2016-06-102019-06-24ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of linagliptin and metformin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6861440B2 (en)*2001-10-262005-03-01Hoffmann-La Roche Inc.DPP IV inhibitors
CA2484306A1 (en)*2002-04-262003-11-06Katsumi MaezonoProphylactic and therapeutic agent of diabetes mellitus
CA2529443C (en)*2003-06-202012-06-05F. Hoffmann-La Roche AgPyrido[2,1-a]-isoquinoline derivatives as dpp-iv inhibitors
JP4227660B2 (en)*2004-05-122009-02-18ファイザー・プロダクツ・インク Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
JP4959569B2 (en)*2004-10-122012-06-27グレンマーク・ファーマシューティカルズ・エスエー Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and processes for preparing them
UY29694A1 (en)*2005-07-282007-02-28Boehringer Ingelheim Int METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO
AU2006290205B2 (en)*2005-09-142012-12-13Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors for treating diabetes
PE20110235A1 (en)*2006-05-042011-04-14Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
WO2007148185A2 (en)*2006-06-212007-12-27Pfizer Products Inc.Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
CL2008000133A1 (en)*2007-01-192008-05-23Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM PIRAZOL-O-GLUCOSIDE COMBINED WITH AT LEAST A SECOND THERAPEUTIC AGENT; AND USE OF THE COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES, CATARATS, NEUROPATHY, MYOCARDIAL INFARTS, AND

Also Published As

Publication numberPublication date
PE20090987A1 (en)2009-08-14
WO2009022009A1 (en)2009-02-19
TW200918078A (en)2009-05-01
CL2008002424A1 (en)2009-09-11
AR068102A1 (en)2009-11-04

Similar Documents

PublicationPublication DateTitle
UY31290A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-O-GLUCOSIDO
UY31291A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO
UY31296A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A SUBSTITUTED BENZENE DERIVATIVE WITH GLUCOPIRANOSIL
UY31295A1 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY AN SGLT2 INHIBITOR
CO6781465A2 (en) Pharmaceutical composition, treatment methods and uses thereof
UY32441A (en) PHARMACEUTICAL COMPOSITION, TREATMENT METHODS AND ITS USES
UY33700A (en) ? PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS ?.
MX387010B (en) SGLT-2 INHIBITOR FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA.
CL2012001043A1 (en) Compounds derived from hexahydroindenopyridine and / or octahydrobenzoquinoline, inhibitors of 11ß-hydroxysteroid dehydrogenase 1 (hsd 1); pharmaceutical compositions comprising the compounds; and use of the compounds for the preparation of medicaments for the treatment of metabolic disorders.
GT200800151A (en) 11-BETA-HSD1 INHIBITORS
CO6270312A2 (en) MODULATORS OF GPR40 BIFENILO-SUBSTITUTES
ECSP099037A (en) METABOLISM MODULATORS AND TREATMENT OF METABOLIC DISORDERS
EA200900940A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PYRAZOL-O-GLUCOSIDE DERIVATIVE
CO6341636A2 (en) DIOXA-BICYCLE DERIVATIVES [3.2.1] OCTANO-2,3,4-TRIOL
CU23815A3 (en) DIARILURES FOR THE TREATMENT OF PULMONARY HYPERTENSION
BR112014025132A2 (en) insulin formulations
AR074302A1 (en) TRANS-CLOMPHENE FOR METABOLIC SYNDROME AND MELLITUS DIABETES TYPE 2 .. METHOD
PA8787001A1 (en) "DERIVATIVES OF MACROLACTONA"
TN2013000187A1 (en)Pharmaceutical composition, methods for treating and uses thereof
ECSP045079A (en) N-REPLACED PIRROLIDIN DERIVATIVES AS INHIBITORS OF DIPEPTIDIL PEPTIDASA IV
DOP2006000249A (en) DIARILURES FOR THE TREATMENT OF PULMONARY HYPERTENSION
CL2010000775A1 (en) Glucopyranosyl substituted 3-benzyl benzene derivative compounds; pharmaceutical composition; pharmaceutical combination comprising said compounds; and its use for the treatment or prevention of metabolic diseases such as diabetes, among others (divisional application 566-05).

Legal Events

DateCodeTitleDescription
109Application deemed to be withdrawn

Effective date:20171011
[8]ページ先頭
©2009-2025 Movatter.jp